Subtopic Deep Dive
Urotensin II Receptor Antagonists
Research Guide
What is Urotensin II Receptor Antagonists?
Urotensin II receptor antagonists are small-molecule and peptide inhibitors targeting the UT receptor (GPR14) to block urotensin II-mediated vasoconstriction in cardiovascular disease models.
Research evaluates these antagonists in preclinical hypertension and vascular models, focusing on species-specific potency differences. Key studies demonstrate UT receptor activation of RhoA/Rho-kinase and NADPH oxidase pathways (Sauzeau et al., 2001; Djordjevic et al., 2004). Over 10 foundational papers from 1980-2014, with Douglas et al. (2000) cited 227 times.
Why It Matters
UT antagonists hold potential for hypertension therapeutics by countering urotensin II's potent vasoconstriction, observed variably across rat, monkey, and human tissues (Douglas et al., 2000; MacLean et al., 2000). They address oxidative stress links in essential hypertension (Rodrigo et al., 2011; González, 2014). Clinical translation could improve outcomes in pulmonary hypertension via NADPH oxidase inhibition (Djordjevic et al., 2004).
Key Research Challenges
Species-variable potency
Human urotensin II shows differential vasoconstriction in rat, mouse, dog, pig, marmoset, and monkey vessels, complicating preclinical models (Douglas et al., 2000). Antagonists must overcome this variability for translation. No selective inhibitors fully match human efficacy yet.
RhoA pathway dependency
hU-II induces contraction and proliferation via RhoA/Rho-kinase, blocked by Y-27632 but requiring antagonist optimization (Sauzeau et al., 2001). Balancing efficacy and off-target effects remains unsolved. Limited structural data hinders design.
Oxidative stress integration
UT activation triggers NADPH oxidase in pulmonary artery cells, linking to hypertension pathophysiology (Djordjevic et al., 2004; Rodrigo et al., 2011). Antagonists must target this without disrupting beneficial signaling. Clinical trials absent.
Essential Papers
The role of oxidative stress in the pathophysiology of hypertension
Ramón Rodrigo, Jaime González, Fabio Paoletto · 2011 · Hypertension Research · 427 citations
Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes.
David Pearson, John E. Shively, Brian R. Clark et al. · 1980 · Proceedings of the National Academy of Sciences · 392 citations
Urotensin II, a peptide hormone from the caudal neurosecretory system of the teleost, Gillichthys mirabilis, was isolated by using classical chromatographic techniques and high-performance liquid c...
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis
Hyung J. Chun, Ziad A. Ali, Yoko Kojima et al. · 2008 · Journal of Clinical Investigation · 324 citations
Apelin and its cognate G protein-coupled receptor APJ constitute a signaling pathway with a positive inotropic effect on cardiac function and a vasodepressor function in the systemic circulation. T...
Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase
Vincent Sauzeau, Erik Le Mellionnec, Jacques Bertoglio et al. · 2001 · Circulation Research · 259 citations
The aim of this work was to investigate the coupling of human urotensin II (hU-II) to RhoA activation and regulation of RhoA-dependent functions. The use of the Rho-kinase inhibitor Y-27632 and the...
Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey
Stephen A. Douglas, Anthony C. Sulpizio, Valerie Piercy et al. · 2000 · British Journal of Pharmacology · 227 citations
Urotensin‐II (U‐II) and its G‐protein‐coupled receptor, GPR14, are expressed within mammalian cardiac and peripheral vascular tissue and, as such, may regulate mammalian cardiovascular function. Th...
Essential hypertension and oxidative stress: New insights
Jaime González · 2014 · World Journal of Cardiology · 194 citations
Essential hypertension is a highly prevalent pathological condition that is considered as one of the most relevant cardiovascular risk factors and is an important cause of morbidity and mortality a...
Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified To Date, as a Therapeutic Target for the Management of Cardiovascular Disease
Stephen A. Douglas, Eliot H. Ohlstein · 2000 · Trends in Cardiovascular Medicine · 193 citations
Reading Guide
Foundational Papers
Start with Douglas et al. (2000) for vasoconstrictor profiles across species, then Sauzeau et al. (2001) for RhoA signaling, and Rodrigo et al. (2011) for hypertension context.
Recent Advances
González (2014) updates essential hypertension oxidative stress; focus on preclinical antagonist gaps post-2011.
Core Methods
Vascular ring assays for pEC50; Y-27632 inhibition of Rho-kinase; NADPH oxidase activity in smooth muscle cells.
How PapersFlow Helps You Research Urotensin II Receptor Antagonists
Discover & Search
Research Agent uses citationGraph on Douglas et al. (2000) to map 227-citation species studies, then findSimilarPapers for antagonist leads; exaSearch queries 'UT receptor inhibitors hypertension preclinical' across 250M+ OpenAlex papers.
Analyze & Verify
Analysis Agent applies readPaperContent to Sauzeau et al. (2001) for Rho-kinase data extraction, verifyResponse (CoVe) on potency claims, and runPythonAnalysis to plot vasoconstrictor pEC50 from Douglas et al. (2000) tables with GRADE scoring for evidence strength.
Synthesize & Write
Synthesis Agent detects gaps in antagonist clinical translation via contradiction flagging on oxidative stress papers (Rodrigo et al., 2011); Writing Agent uses latexEditText, latexSyncCitations for Douglas et al., and latexCompile to generate review manuscripts with exportMermaid for RhoA signaling diagrams.
Use Cases
"Analyze vasoconstrictor potency data from urotensin II across species in Douglas 2000."
Research Agent → searchPapers('Douglas 2000 urotensin') → Analysis Agent → readPaperContent → runPythonAnalysis (pandas plot pEC50 curves) → matplotlib figure of species differences.
"Draft LaTeX review on UT antagonists and Rho-kinase inhibition."
Synthesis Agent → gap detection (Sauzeau 2001 + Douglas 2000) → Writing Agent → latexEditText (structure sections) → latexSyncCitations → latexCompile → PDF with RhoA pathway Mermaid diagram.
"Find code for UT receptor signaling simulations from related papers."
Research Agent → citationGraph (Sauzeau 2001) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python models of Rho-kinase inhibition.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'urotensin II antagonists hypertension', structures report with GRADE grading on preclinical efficacy. DeepScan applies 7-step CoVe to verify Douglas et al. (2000) potency claims against Rodrigo et al. (2011) oxidative stress data. Theorizer generates hypotheses on UT-NADPH oxidase links from Djordjevic et al. (2004).
Frequently Asked Questions
What defines urotensin II receptor antagonists?
Small-molecule and peptide inhibitors of the UT (GPR14) receptor blocking hU-II vasoconstriction, evaluated in hypertension models (Douglas et al., 2000).
What are key methods in this research?
Isolated vessel assays measure pEC50 vasoconstriction; Rho-kinase inhibitors like Y-27632 test pathways; NADPH oxidase assays link to oxidative stress (Sauzeau et al., 2001; Djordjevic et al., 2004).
What are foundational papers?
Douglas et al. (2000, 227 citations) on species potency; Sauzeau et al. (2001, 259 citations) on RhoA mechanisms; Rodrigo et al. (2011, 427 citations) on hypertension oxidative stress.
What open problems exist?
Lack of human-selective antagonists due to species variability; no clinical trials; integrating UT blockade with oxidative stress therapies (González, 2014).
Research Cardiovascular, Neuropeptides, and Oxidative Stress Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Urotensin II Receptor Antagonists with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers